Skip to main content
PMC home page
The Journal of Experimental Medicine logoLink to The Journal of Experimental Medicine
. 1995 Jul 1;182(1):267–272. doi: 10.1084/jem.182.1.267

Triglyceride-rich lipoproteins prevent septic death in rats

PMCID: PMC2192094  PMID: 7790821

Abstract

Triglyceride-rich lipoproteins bind and inactive bacterial endotoxin in vitro and prevent death when given before a lethal dose of endotoxin in animals. However, lipoproteins have not yet been demonstrated to improve survival in polymicrobial gram-negative sepsis. We therefore tested the ability of triglyceride-rich lipoproteins to prevent death after cecal ligation and puncture (CLP) in rats. Animals were given bolus infusions of either chylomicrons (1 g triglyceride/kg per 4 h) or an equal volume of saline for 28 h after CLP. Chylomicron infusions significantly improved survival (measured at 96 h) compared with saline controls (80 vs 27%, P < or = 0.03). Chylomicron infusions also reduced serum levels of endotoxin, measured 90 min (26 +/- 3 vs 136 +/- 51 pg/ml, mean +/- SEM, P < or = 0.03) and 6 h (121 +/- 54 vs 1,026 +/- 459 pg/ml, P < or = 0.05) after CLP. The reduction in serum endotoxin correlated with a reduction in serum tumor necrosis factor, measured 6 h after CLP (0 +/- 0 vs 58 +/- 24 pg/ml, P < or = 0.03), suggesting that chylomicrons improve survival in this model by limiting macrophage exposure to endotoxin and thereby reducing secretion of inflammatory cytokines. Infusions of a synthetic triglyceride-rich lipid emulsion (Intralipid; KabiVitrum, Inc., Alameda, CA) (1 g triglyceride/kg) also significantly improved survival compared with saline controls (71 vs 27%, P < or = 0.03). These data demonstrate that triglyceride-rich lipoproteins can protect animals from lethal polymicrobial gram- negative sepsis.

Full Text

The Full Text of this article is available as a PDF (570.3 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Alexander H. R., Sheppard B. C., Jensen J. C., Langstein H. N., Buresh C. M., Venzon D., Walker E. C., Fraker D. L., Stovroff M. C., Norton J. A. Treatment with recombinant human tumor necrosis factor-alpha protects rats against the lethality, hypotension, and hypothermia of gram-negative sepsis. J Clin Invest. 1991 Jul;88(1):34–39. doi: 10.1172/JCI115298. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. BRAUDE A. I., CAREY F. J., ZALESKY M. Studies with radioactive endotoxin. II. Correlation of physiologic effects with distribution of radioactivity in rabbits injected with radioactive sodium chromate. J Clin Invest. 1955 Jun;34(6):858–866. doi: 10.1172/JCI103141. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Beutler B. A., Cerami A. Recombinant interleukin 1 suppresses lipoprotein lipase activity in 3T3-L1 cells. J Immunol. 1985 Dec;135(6):3969–3971. [PubMed] [Google Scholar]
  4. Castell J. V., Gómez-Lechón M. J., David M., Andus T., Geiger T., Trullenque R., Fabra R., Heinrich P. C. Interleukin-6 is the major regulator of acute phase protein synthesis in adult human hepatocytes. FEBS Lett. 1989 Jan 2;242(2):237–239. doi: 10.1016/0014-5793(89)80476-4. [DOI] [PubMed] [Google Scholar]
  5. Cavaillon J. M., Fitting C., Haeffner-Cavaillon N., Kirsch S. J., Warren H. S. Cytokine response by monocytes and macrophages to free and lipoprotein-bound lipopolysaccharide. Infect Immun. 1990 Jul;58(7):2375–2382. doi: 10.1128/iai.58.7.2375-2382.1990. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Chisari F. V., Curtiss L. K., Jensen F. C. Physiologic concentrations of normal human plasma lipoproteins inhibit the immortalization of peripheral B lymphocytes by the Epstein-Barr virus. J Clin Invest. 1981 Aug;68(2):329–336. doi: 10.1172/JCI110260. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Darlington G. J., Wilson D. R., Lachman L. B. Monocyte-conditioned medium, interleukin-1, and tumor necrosis factor stimulate the acute phase response in human hepatoma cells in vitro. J Cell Biol. 1986 Sep;103(3):787–793. doi: 10.1083/jcb.103.3.787. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Dofferhoff A. S., Bom V. J., de Vries-Hospers H. G., van Ingen J., vd Meer J., Hazenberg B. P., Mulder P. O., Weits J. Patterns of cytokines, plasma endotoxin, plasminogen activator inhibitor, and acute-phase proteins during the treatment of severe sepsis in humans. Crit Care Med. 1992 Feb;20(2):185–192. doi: 10.1097/00003246-199202000-00007. [DOI] [PubMed] [Google Scholar]
  9. Eichbaum E. B., Harris H. W., Kane J. P., Rapp J. H. Chylomicrons can inhibit endotoxin activity in vitro. J Surg Res. 1991 Nov;51(5):413–416. doi: 10.1016/0022-4804(91)90143-a. [DOI] [PubMed] [Google Scholar]
  10. Emancipator K., Csako G., Elin R. J. In vitro inactivation of bacterial endotoxin by human lipoproteins and apolipoproteins. Infect Immun. 1992 Feb;60(2):596–601. doi: 10.1128/iai.60.2.596-601.1992. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Espevik T., Nissen-Meyer J. A highly sensitive cell line, WEHI 164 clone 13, for measuring cytotoxic factor/tumor necrosis factor from human monocytes. J Immunol Methods. 1986 Dec 4;95(1):99–105. doi: 10.1016/0022-1759(86)90322-4. [DOI] [PubMed] [Google Scholar]
  12. Feingold K. R., Grunfeld C. Tumor necrosis factor-alpha stimulates hepatic lipogenesis in the rat in vivo. J Clin Invest. 1987 Jul;80(1):184–190. doi: 10.1172/JCI113046. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Feingold K. R., Soued M., Serio M. K., Moser A. H., Dinarello C. A., Grunfeld C. Multiple cytokines stimulate hepatic lipid synthesis in vivo. Endocrinology. 1989 Jul;125(1):267–274. doi: 10.1210/endo-125-1-267. [DOI] [PubMed] [Google Scholar]
  14. Feingold K. R., Staprans I., Memon R. A., Moser A. H., Shigenaga J. K., Doerrler W., Dinarello C. A., Grunfeld C. Endotoxin rapidly induces changes in lipid metabolism that produce hypertriglyceridemia: low doses stimulate hepatic triglyceride production while high doses inhibit clearance. J Lipid Res. 1992 Dec;33(12):1765–1776. [PubMed] [Google Scholar]
  15. Flegel W. A., Wölpl A., Männel D. N., Northoff H. Inhibition of endotoxin-induced activation of human monocytes by human lipoproteins. Infect Immun. 1989 Jul;57(7):2237–2245. doi: 10.1128/iai.57.7.2237-2245.1989. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Freudenberg M., Galanos C. Metabolic fate of endotoxin in rat. Adv Exp Med Biol. 1990;256:499–509. doi: 10.1007/978-1-4757-5140-6_44. [DOI] [PubMed] [Google Scholar]
  17. Grunfeld C., Adi S., Soued M., Moser A., Fiers W., Feingold K. R. Search for mediators of the lipogenic effects of tumor necrosis factor: potential role for interleukin 6. Cancer Res. 1990 Jul 15;50(14):4233–4238. [PubMed] [Google Scholar]
  18. Harris H. W., Eichbaum E. B., Kane J. P., Rapp J. H. Detection of endotoxin in triglyceride-rich lipoproteins in vitro. J Lab Clin Med. 1991 Aug;118(2):186–193. [PubMed] [Google Scholar]
  19. Harris H. W., Grunfeld C., Feingold K. R., Rapp J. H. Human very low density lipoproteins and chylomicrons can protect against endotoxin-induced death in mice. J Clin Invest. 1990 Sep;86(3):696–702. doi: 10.1172/JCI114765. [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. Harris H. W., Grunfeld C., Feingold K. R., Read T. E., Kane J. P., Jones A. L., Eichbaum E. B., Bland G. F., Rapp J. H. Chylomicrons alter the fate of endotoxin, decreasing tumor necrosis factor release and preventing death. J Clin Invest. 1993 Mar;91(3):1028–1034. doi: 10.1172/JCI116259. [DOI] [PMC free article] [PubMed] [Google Scholar]
  21. Harris R. I., Stone P. C., Stuart J. An improved chromogenic substrate endotoxin assay for clinical use. J Clin Pathol. 1983 Oct;36(10):1145–1149. doi: 10.1136/jcp.36.10.1145. [DOI] [PMC free article] [PubMed] [Google Scholar]
  22. Kushner I. The phenomenon of the acute phase response. Ann N Y Acad Sci. 1982;389:39–48. doi: 10.1111/j.1749-6632.1982.tb22124.x. [DOI] [PubMed] [Google Scholar]
  23. Marinkovic S., Jahreis G. P., Wong G. G., Baumann H. IL-6 modulates the synthesis of a specific set of acute phase plasma proteins in vivo. J Immunol. 1989 Feb 1;142(3):808–812. [PubMed] [Google Scholar]
  24. Mathison J. C., Ulevitch R. J. The clearance, tissue distribution, and cellular localization of intravenously injected lipopolysaccharide in rabbits. J Immunol. 1979 Nov;123(5):2133–2143. [PubMed] [Google Scholar]
  25. Munford R. S., Hall C. L., Lipton J. M., Dietschy J. M. Biological activity, lipoprotein-binding behavior, and in vivo disposition of extracted and native forms of Salmonella typhimurium lipopolysaccharides. J Clin Invest. 1982 Oct;70(4):877–888. doi: 10.1172/JCI110684. [DOI] [PMC free article] [PubMed] [Google Scholar]
  26. Owens B. J., Anantharamaiah G. M., Kahlon J. B., Srinivas R. V., Compans R. W., Segrest J. P. Apolipoprotein A-I and its amphipathic helix peptide analogues inhibit human immunodeficiency virus-induced syncytium formation. J Clin Invest. 1990 Oct;86(4):1142–1150. doi: 10.1172/JCI114819. [DOI] [PMC free article] [PubMed] [Google Scholar]
  27. Patton J. S., Shepard H. M., Wilking H., Lewis G., Aggarwal B. B., Eessalu T. E., Gavin L. A., Grunfeld C. Interferons and tumor necrosis factors have similar catabolic effects on 3T3 L1 cells. Proc Natl Acad Sci U S A. 1986 Nov;83(21):8313–8317. doi: 10.1073/pnas.83.21.8313. [DOI] [PMC free article] [PubMed] [Google Scholar]
  28. Pekala P. H., Kawakami M., Angus C. W., Lane M. D., Cerami A. Selective inhibition of synthesis of enzymes for de novo fatty acid biosynthesis by an endotoxin-induced mediator from exudate cells. Proc Natl Acad Sci U S A. 1983 May;80(9):2743–2747. doi: 10.1073/pnas.80.9.2743. [DOI] [PMC free article] [PubMed] [Google Scholar]
  29. Perlmutter D. H., Dinarello C. A., Punsal P. I., Colten H. R. Cachectin/tumor necrosis factor regulates hepatic acute-phase gene expression. J Clin Invest. 1986 Nov;78(5):1349–1354. doi: 10.1172/JCI112721. [DOI] [PMC free article] [PubMed] [Google Scholar]
  30. Read T. E., Harris H. W., Grunfeld C., Feingold K. R., Calhoun M. C., Kane J. P., Rapp J. H. Chylomicrons enhance endotoxin excretion in bile. Infect Immun. 1993 Aug;61(8):3496–3502. doi: 10.1128/iai.61.8.3496-3502.1993. [DOI] [PMC free article] [PubMed] [Google Scholar]
  31. Rifkin M. R. Identification of the trypanocidal factor in normal human serum: high density lipoprotein. Proc Natl Acad Sci U S A. 1978 Jul;75(7):3450–3454. doi: 10.1073/pnas.75.7.3450. [DOI] [PMC free article] [PubMed] [Google Scholar]
  32. Robinson S. F., Quarfordt S. H. Apoproteins in association with Intralipid incubations in rat and human plasma. Lipids. 1979 Apr;14(4):343–349. doi: 10.1007/BF02533417. [DOI] [PubMed] [Google Scholar]
  33. Sernatinger J., Hoffman A., Hardman D., Kane J. P., Levy J. A. Neutralization of mouse xenotropic virus by lipoproteins involves binding to the virions. J Gen Virol. 1988 Oct;69(Pt 10):2657–2661. doi: 10.1099/0022-1317-69-10-2657. [DOI] [PubMed] [Google Scholar]
  34. Stein O., Stein Y., Goodman D. S., Fidge N. H. The metabolism of chylomicron cholesteryl ester in rat liver. A combined radioautographic-electron microscopic and biochemical study. J Cell Biol. 1969 Dec;43(3):410–431. doi: 10.1083/jcb.43.3.410. [DOI] [PMC free article] [PubMed] [Google Scholar]
  35. Terkeltaub R., Curtiss L. K., Tenner A. J., Ginsberg M. H. Lipoproteins containing apoprotein B are a major regulator of neutrophil responses to monosodium urate crystals. J Clin Invest. 1984 Jun;73(6):1719–1730. doi: 10.1172/JCI111380. [DOI] [PMC free article] [PubMed] [Google Scholar]
  36. Ulevitch R. J., Johnston A. R. The modification of biophysical and endotoxic properties of bacterial lipopolysaccharides by serum. J Clin Invest. 1978 Dec;62(6):1313–1324. doi: 10.1172/JCI109252. [DOI] [PMC free article] [PubMed] [Google Scholar]
  37. Ulevitch R. J., Johnston A. R., Weinstein D. B. New function for high density lipoproteins. Their participation in intravascular reactions of bacterial lipopolysaccharides. J Clin Invest. 1979 Nov;64(5):1516–1524. doi: 10.1172/JCI109610. [DOI] [PMC free article] [PubMed] [Google Scholar]
  38. Van Bossuyt H., De Zanger R. B., Wisse E. Cellular and subcellular distribution of injected lipopolysaccharide in rat liver and its inactivation by bile salts. J Hepatol. 1988 Dec;7(3):325–337. doi: 10.1016/s0168-8278(88)80005-9. [DOI] [PubMed] [Google Scholar]
  39. Victorov A. V., Medvedeva N. V., Gladkaya E. M., Morozkin A. D., Podrez E. A., Kosykh V. A., Yurkiv V. A. Composition and structure of lipopolysaccharide-human plasma low density lipoprotein complex. Analytical ultracentrifugation, 31P-NMR, ESR and fluorescence spectroscopy studies. Biochim Biophys Acta. 1989 Aug 21;984(1):119–127. doi: 10.1016/0005-2736(89)90351-9. [DOI] [PubMed] [Google Scholar]
  40. Vilaró S., Llobera M. Uptake and metabolism of Intralipid by rat liver: an electron-microscopic study. J Nutr. 1988 Aug;118(8):932–940. doi: 10.1093/jn/118.8.932. [DOI] [PubMed] [Google Scholar]
  41. Wichterman K. A., Baue A. E., Chaudry I. H. Sepsis and septic shock--a review of laboratory models and a proposal. J Surg Res. 1980 Aug;29(2):189–201. doi: 10.1016/0022-4804(80)90037-2. [DOI] [PubMed] [Google Scholar]

Articles from The Journal of Experimental Medicine are provided here courtesy of The Rockefeller University Press

RESOURCES